KATHERINE FLYNN: Open Payments
NPI 1639654171 · BROOKHAVEN, MS. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$679 in 31 payments from 11 companies in 2025. Trend: 2023 $238 · 2024 $347 · 2025 $679
Food & beverage: $679
| Company | Payments | Amount |
|---|---|---|
| Vanda Pharmaceuticals Inc. | 8 | $193 |
| ABBVIE INC. | 5 | $105 |
| HARMONY BIOSCIENCES LLC | 3 | $97 |
| Lundbeck LLC | 3 | $60 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 3 | $56 |
| Janssen Pharmaceuticals, Inc | 2 | $38 |
| Otsuka America Pharmaceutical, Inc. | 2 | $36 |
| Supernus Pharmaceuticals, Inc. | 2 | $29 |
| Neurocrine BioSciences, Inc. | 1 | $28 |
| Tris Pharma Inc | 1 | $20 |
Products named: FANAPT, VRAYLAR, WAKIX, REXULTI, CAPLYTA, SPRAVATO, Qelbree, INGREZZA.
Industry payments across MS — which companies pay providers there.
